financial results
In Brief This Week: Myriad Genetics, Thermo Fisher Scientific, DeepUll, Roche, Immunovia, More
News items for the weeks of Nov. 25 and Dec. 2, 2024.
Prenetics Q3 Revenues up 59 Percent
The company's CircleDNA and ACT Genomics businesses are on track to achieve business-unit breakeven in the second half of 2024, it said.
The company also said that its Diagnostics and Genomics revenues were down 1 percent during fiscal Q4, although its overall revenues were up slightly.
In Brief This Week: Quest Diagnostics, T2 Biosystems, Oncocyte, Myriad Genetics, More
News items for the week of Nov. 11, 2024
Natera Q3 Revenues Grow 64 Percent
Strong product sales, mainly from oncology tests, drove the company's revenue growth, prompting it to raise its full year guidance.
Nov 12, 2024
Grail Q3 Revenues Rise 39 Percent
Nov 12, 2024
Exagen Q3 Revenues Decline 7 Percent
Nov 7, 2024
Becton Dickinson Q4 Revenues Grow 7 Percent
Nov 5, 2024
Sophia Genetics Q3 Revenues Fall 3 Percent
Nov 5, 2024
NeoGenomics Q3 Revenues up 10 Percent
Nov 5, 2024